Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC decreased its position in Edwards Lifesciences Co. (NYSE:EW) by 4.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 76,162 shares of the medical research company’s stock after selling 3,539 shares during the period. Mutual of America Capital Management LLC’s holdings in Edwards Lifesciences were worth $7,035,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. DSM Capital Partners LLC acquired a new stake in Edwards Lifesciences during the 4th quarter worth about $28,000. Crewe Advisors LLC purchased a new position in Edwards Lifesciences during the first quarter valued at approximately $28,000. First Community Trust NA acquired a new position in Edwards Lifesciences in the second quarter valued at approximately $29,000. Riverview Trust Co acquired a new position in Edwards Lifesciences in the first quarter valued at approximately $34,000. Finally, Pingora Partners LLC purchased a new position in shares of Edwards Lifesciences during the 4th quarter valued at approximately $38,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 0.4 %

Shares of EW opened at $67.26 on Friday. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. The firm has a 50-day moving average price of $70.37 and a 200 day moving average price of $83.00. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The firm has a market capitalization of $40.53 billion, a P/E ratio of 28.99, a P/E/G ratio of 2.85 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. The firm had revenue of $1.63 billion for the quarter, compared to analyst estimates of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.66 EPS. Sell-side analysts forecast that Edwards Lifesciences Co. will post 2.7 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total transaction of $333,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,133,916.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total value of $333,850.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,133,916.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,250 shares of company stock worth $1,218,138. 1.29% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

EW has been the topic of a number of recent analyst reports. Robert W. Baird downgraded shares of Edwards Lifesciences from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $102.00 to $70.00 in a report on Thursday, July 25th. TD Cowen cut Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their target price for the company from $100.00 to $70.00 in a research report on Thursday, July 25th. Barclays lowered their price target on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Piper Sandler cut their price objective on Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating for the company in a research report on Thursday, July 25th. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, July 25th. Sixteen research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $79.82.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.